The MarketWatch News Department was not involved in the creation of this content. GREENVILLE, S.C. and SACRAMENTO, Calif., Jan. 6, 2026 /PRNewswire/ -- PAI Pharma ("PAI"), a portfolio company of ...

Novel 505(b)(2) presentation of a key injectable for treating non-squamous non-small cell lung cancer and malignant pleural mesothelioma, does not require reconstitution, dilution, or refrigeration ...

Amneal is expanding its injectables portfolio with six new injectable product launches during the second quarter of 2024, bringing the company’s total number of commercial injectable products ...

The Food and Drug Administration has approved Amneal’s Pemrydi RTU, the only ready-to-use presentation of pemetrexed for injection and does not require reconstitution, dilution or refrigeration. This ...

- Adds first ready-to-use presentation of key injectable for treating non-squamous non-small cell lung cancer and malignant pleural mesothelioma - Represents a high value, complex product launch for ...

(MENAFN- GlobeNewsWire - Nasdaq) Dublin, Nov. 06, 2024 (GLOBE NEWSWIRE) -- The "Sterile Injectable Drugs - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

CHICAGO--(BUSINESS WIRE)-- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ...

Market advances adoption of ready-to-use containers Improved operational efficiency in pharmaceutical manufacturing processes Increased patient safety with high-quality sterile primary packaging ...

GREENVILLE, S.C. and SACRAMENTO, Calif., Jan. 6, 2026 /PRNewswire/ -- PAI Pharma ("PAI"), a portfolio company of Olympus Partners and a leading U.S. developer, manufacturer and marketer of oral liquid ...

- Adds first ready-to-use presentation of key injectable for treating non-squamous non-small cell lung cancer and malignant pleural mesothelioma BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal ...